Classification of triple negative breast cancer by epithelial mesenchymal transition and the tumor immune microenvironment
Abstract Triple-negative breast cancer (TNBC) accounts for about 15–20% of all breast cancers and differs from other invasive breast cancer types because it grows and spreads rapidly, it has limited treatment options and typically worse prognosis. Since TNBC does not express estrogen or progesterone...
Main Authors: | Francesc Font-Clos, Stefano Zapperi, Caterina A. M. La Porta |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-06-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-022-13428-2 |
Similar Items
-
The Response of Triple-Negative Breast Cancer to Neoadjuvant Chemotherapy and the Epithelial–Mesenchymal Transition
by: Stefano Zapperi, et al.
Published: (2023-03-01) -
Integrative analysis of pathway deregulation in obesity
by: Francesc Font-Clos, et al.
Published: (2017-06-01) -
Blood Flow Contributions to Cancer Metastasis
by: Francesc Font-Clos, et al.
Published: (2020-05-01) -
PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer
by: Ghaneya Al-Khadairi, et al.
Published: (2019-01-01) -
Novel Diphenylamine Analogs Induce Mesenchymal to Epithelial Transition in Triple Negative Breast Cancer
by: Akshita B. Bhatt, et al.
Published: (2019-07-01)